Literature DB >> 2076597

In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent.

G M Eliopoulos1, K Klimm, M L Grayson.   

Abstract

In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501) against clinical bacterial isolates was compared with those of ciprofloxacin and vancomycin or imipenem. Sparfloxacin was more active or equal to ciprofloxacin against most Gram-positive species and against Bacteroides fragilis, and it inhibited virtually all Enterobacteriaceae at 1.0 micrograms/ml or less.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2076597     DOI： 10.1016/0732-8893(90)90029-u

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  9 in total

1.  Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.

Authors:  P C Fuchs; A L Barry; M A Pfaller
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

2.  Anti-Mycobacterium avium activity of quinolones: in vitro activities.

Authors:  G Klopman; S Wang; M R Jacobs; S Bajaksouzian; K Edmonds; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

3.  Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.

Authors:  A L Barry; P C Fuchs; S D Allen; J H Jorgensen; F C Tenover; P R Murray; D J Hardy; C N Baker
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

4.  Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.

Authors:  L D Sutton; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

5.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 6.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 7.  Activity of quinolones against mycobacteria.

Authors:  M R Jacobs
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.

Authors:  J C Akaniro; H R Stutman; A G Arguedas; O M Vargas
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 9.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.